Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MasterCard Inc (MA) vs ResMed Inc. (RMD) Price & Performance

MasterCard IncTrade
ResMed Inc.Trade

Price performance (Past 24H)

Key statistics

MasterCard Inc vs ResMed Inc. — how do they compare? MasterCard Inc trades at $559 (market cap $491.83B), while ResMed Inc. trades at $220.4 (market cap $32.61B). The key difference: MasterCard Inc is far larger — about 15.1× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.17%). Which is the better fit depends on your goals.

MARMD
Market Cap
$491.83B$32.61B
Volume
4,635,698
Sector
Consumer CyclicalHealth
52-Week High
$598.96$293.73
52-Week Low
$471.55$182.82
Enterprise Value
$504.86B$31.97B
Dividend Yield
0.62%1.17%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MasterCard Inc

Mastercard (MA) trades at $563.17, up 0.04% today, with a bullish technical signal and strong institutional buying. The stock shows robust fundamentals, with revenue growing from $22.2B in 2022 to $32.8B in 2025 and net income margins above 45%. Recent earnings beats and a consensus price target of $660.85 reflect optimism, though high valuation ratios like a P/E of 30.98 warrant caution.

Outlook is positive due to consistent earnings growth, expanding digital payment initiatives, and analyst buy ratings. Risks include competitive pressures from new payment technologies and regulatory scrutiny. The stock offers upside potential but requires monitoring of valuation and market shifts.

ResMed Inc.

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About MasterCard Inc

Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.

Read more on MA

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD